Monday, October 30, 2017

Bioscience Developments - An Integrated BioSci Investing Report

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Sunday, October 29, 2017

Helping The Torch Foundation - An Integrated BioSci Investing Outreach

Summary


  • Torch Foundation is helping underprivileged American teens.
  • You're invited to the masquerade ball fundraising event on Nov. 1st.
  • Consider donating to the foundation even if you cannot participate in the said event.


Dear investors,


I'm writing on the behalf of my friend, Joe Hang, who is an activist helping underprivileged teenage American girls (age 13-17). Empowering America's youth (and donating school supplies to kids), Joe works with the organization in raising money to support their mission. The aforesaid organization is holding a masquerade ball fundraiser event (on Nov. 1). It will be held at 930 S. San Pedro, Los Angeles CA 90015. You all are invited to the event.


I already contributed my small share by donating through my marketplace research, Integrated BioSci Investing. And, I am reaching out to you to consider donating (to the purpose greater than that of ourselves), even if you cannot attend the event.
You should pass along the help to others, especially if you've benefited much from my recommendations on stellar biosciences firms (such as Spectrum Pharmaceuticals (NASDAQ:SPPI), Exelixis (NASDAQ:EXEL), Gilead Sciences (NASDAQ:GILD), Kite Pharma (NASDAQ:KITE), Alpine Immune Sciences (NASDAQ:OTC:ALPN), and Nektar Therapeutics (NASDAQ:NKTR).


Source: Dr. Tran BioSci (Adapted from Google Finance)


Together, we can build a better future for America. All your efforts count. Here is the link to their website, where you can make your donation. Thank you all for your readership and support.


Sincerely,

Dr. Tran
Chief Medical Analyst, Integrated BioSci Investing

Wednesday, October 25, 2017

Insight From The Stellar Scientist Trader - An Integrated BioSci Investing Report

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Sunday, October 22, 2017

Elucidating The Ramifications Of The Celestial Trial

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Integrated BioSci Investing: Latest Bioscience Breakthroughs

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Friday, October 20, 2017

Integrated BioSci Investing: CAR-T FDA Approved And Promising Developments

Summary

  • CAR-TCR received FDA approval for the treatment of non-Hodgkin lymphoma.
  • Kite, Exelixis, and Spectrum are delivering stellar returns for subscribers.
  • We intend to increase the forecasting of both clinical and regulatory catalysts.
  • Integrated BioSci Investing portfolio is yielding an overall robust return.

The biotech sector is highly promising with merger and acquisition to boost for stellar profits. In the past 52-weeks, Kite Pharma (NASDAQ:KITE) was acquired by Gilead Sciences Inc (NASDAQ:GILD) for $11.9B (on Aug. 28, 2017). This catapulted our portfolio’s profits on Kite to 82%. As this story is playing out, the FDA approved CAR-TCR as the treatment for non-Hodgkin lymphoma (on Oct. 18, 2017). The stellar news (for both patients and investors) gives further credence to our thesis on CAR-TCR (as a major breakthrough since the introduction of chemotherapy, half a decade prior).

Tuesday, October 17, 2017

Stellar BioSciences For Value Investors

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.